Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome

Timothy M. Kuzel*, Henry H. Roenigk, Ellen Samuelson, James J. Herrmann, Arti Hurria, Alfred W. Rademaker, Steven T. Rosen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

160 Scopus citations


Purpose: To investigate the efficacy of combined topical therapy and systemic interferon alfa-2a in patients with mycosis fungoides (MF) and the Sézary syndrome (SS). Patients and Methods: Between December 1987 and April 1993, 39 patients with all stages of MF and SS were treated with combined phototherapy and systemic interferon alfa-2a as part of two institutional studies. The initial phase I study of 15 patients established the maximum-tolerated dose of interferon and has been previously reported. Subsequently, 24 patients have been entered onto a phase II trial. Long-term follow-up data are provided for both studies. Results: The median follow-up duration for the entire cohort is 28 months. Patients with all stages of disease were enrolled (stage IB, n = 14; IIA, n = 5; IIB, n = 6; III, n = 8; IVA, n = 5; IVB, n = 1). Thirty-four patients had received previous therapy. Overall, 36 of 39 patients achieved a complete response (CR; 62%) or partial response (28%) to therapy. The median response duration is 28 months (range, 1 to 64). Twenty-nine of 39 patients are alive, with a median survival duration of 62 months (range, 1 to 66). Conclusion: Interferon alfa-2a combined with phototherapy is an effective, safe, durable therapy for MF and SS.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalJournal of Clinical Oncology
Issue number1
StatePublished - Jan 1 1995

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome'. Together they form a unique fingerprint.

Cite this